Verve Therapeutics (NASDAQ:VERV) Receives Outperform Rating from William Blair

William Blair restated their outperform rating on shares of Verve Therapeutics (NASDAQ:VERV) in a research report report published on Friday,RTT News reports.

A number of other research analysts have also commented on the company. Canaccord Genuity Group upped their target price on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright lowered their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reduced their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $25.75.

Verve Therapeutics Stock Down 7.0 %

Verve Therapeutics stock opened at $7.28 on Friday. The business has a 50 day moving average price of $6.80 and a two-hundred day moving average price of $5.96. Verve Therapeutics has a 12 month low of $4.30 and a 12 month high of $19.34. The stock has a market cap of $616.32 million, a price-to-earnings ratio of -2.96 and a beta of 1.74.

Hedge Funds Weigh In On Verve Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BVF Inc. IL raised its stake in Verve Therapeutics by 962.2% during the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company’s stock worth $38,939,000 after acquiring an additional 6,254,050 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Verve Therapeutics in the 4th quarter worth about $7,863,000. Schonfeld Strategic Advisors LLC grew its holdings in shares of Verve Therapeutics by 57.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company’s stock worth $21,372,000 after purchasing an additional 1,382,176 shares during the last quarter. State Street Corp increased its position in shares of Verve Therapeutics by 27.0% during the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company’s stock worth $20,586,000 after purchasing an additional 903,809 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Verve Therapeutics by 72.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company’s stock valued at $7,547,000 after purchasing an additional 653,578 shares during the last quarter. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.